MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 7, 2017, Executive Vice President Research and Development Paul W. Maffuid, Ph.D. rescinded his notice of intent to terminate his employment agreement with MabVax Therapeutics Holdings, Inc. (the “Company”) for “Good Reason” as that term is defined in his employment agreement. Also on September 7, 2017, the Company re-instated the salary and restored previously deferred amounts of Vice President and Chief Business Officer Paul F. Resnick, M.D., thus curing the condition that resulted in his claim to terminate his employment for “Good Reason” and providing for his continued employment.
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Recent Trading Information
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) closed its last trading session 00.000 at 0.480 with 173,229 shares trading hands.
